Effect of ensure on the oral bioavailability of gatifloxacin in healthy volunteers

Pharmacotherapy

Volumn 25, Issue 11 I, 2005, Pages 1530-1535

  Kays, Michael B ^a,b   Overholser, Brian R ^a,b   Lagvankar, Seema ^b   Goldman, Mitchell ^b   Sowinski, Kevin M ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ensure; Enteral nutrition; Gatifloxacin; Oral bioavailability; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; ENSURE; GATIFLOXACIN; INFUSION FLUID; OSMOLITE; SUSTACAL; TROVAFLOXACIN;

ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL MILK; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; ENTERIC FEEDING; FEMALE; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PATIENT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TUBE FEEDING;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY SUCROSE; ENTERAL NUTRITION; FEMALE; FLUOROQUINOLONES; HUMANS; KIDNEY; MALE;

EID: 27644577713     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11.1530     Document Type: Article

References (28)

1. Hoellman DB, Lin G, Jacobs MR, Appelbaum PC. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 1999;43:645-9.
2. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437-46.
3. Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 2002;50:495-502.
4. White RL, Enzweiler KA, Friedrich LV, Wagner D, Hoban D, Bosso JA. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneutnoniae in the United States during 1999-2000. Diagn Microbiol Infect Dis 2002;43:207-17.
5. Dubois J, St-Pierre C. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn Microbiol Infect Dis 1999;33;261-5.
6. Roblin PM, Hammerschlag MR. In-vitro activity of gatifloxacin against Chlamydia irochomatis and Chlamydia pneumoniae. J Antimicrob Chemother 1999;44:549-51.
7. Ishida K, Kaku M, Irifune K, et al. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasme pneumoniae. J Antimicrob Chemother 1994;34:875-83.
8. Dubois J, St-Pierre C. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens. Diagn Microbiol Infect Dis 2001;40:35-40.
9. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
10. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
11. Craig WA. Pharmacokinetic-pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
12. LaCreta FP, Kaul S, Kollia GD, Duncan G, Randall DM, Grasela DM. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. Pharmacotherapy 2000;20(6 pt 2):59S-66.
13. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292-7.
14. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21(10 pt 2):253S-72.
15. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002;62:13-59.
16. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 1996;40:6-10.
17. Mueller BA, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994;38:2101-5.
18. Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enteral Nutr 2000;24:42-8.
19. Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother 1989;33:1118-20.
20. Vincent J, Teng R, Pelletier SM, Willavize SA, Friedman HL. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. Am J Surg 1998;176(suppl 6A):S23-6.
21. Kanji S, McKinnon PS, Barletta JF, Kruse JA, Devlin JW. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Crit Care Med 2003;31:1347-52.
22. Overholser BR, Kays MB, Sowinski KM. Determination of gatifloxacin in human serum and urine by high performance liquid chromatography with ultraviolet detection. J Chromatog B Analyt Technol Biomed Life Sci 2003;798:167-73.
23. Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Rockville, MD: U.S. Department of Health and Human Services, 2002.
24. Lubowski TJ, Nightingale CH, Sweeney K, Quintiliani R. The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding. Clin Pharmacokinet 1992;22(snppl I):43-7.
25. Cohn SM, Sawyer MD, Burns GA, Tolomeo C, Milner KA. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother 1996;38:871-6.
26. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med 1998;24:1047-51.
27. Nakashima M, Oematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995;39:2635-40.
28. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000;20(6 pt 2):49S-58.